AngioDynamics Inc Cash Flow Conversion Efficiency
AngioDynamics Inc cash flow conversion efficiency. Based on the latest financial reports, AngioDynamics Inc (ANGO) has a cash flow conversion efficiency ratio of 0.102x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($17.45 Million) by net assets ($170.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AngioDynamics Inc (2002–2026)
Cash flow conversion efficiency of AngioDynamics Inc from 2002 to 2026. This chart illustrates how AngioDynamics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AngioDynamics Inc stock price for real-time trading data and today's change.
AngioDynamics Inc Cash Flow Conversion Ratio Explained
AngioDynamics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AngioDynamics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AngioDynamics Inc ranked by their cash flow conversion efficiency. Also see market value of AngioDynamics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stendörren Fastigheter AB (publ)
ST:STEF-B
|
0.016x |
|
Shandong Shuangyi Technology Co Ltd
SHE:300690
|
0.024x |
|
Sebang Global Battery Co Ltd
KO:004490
|
0.042x |
|
Enterprise Bancorp Inc
NASDAQ:EBTC
|
0.014x |
|
CoinShares PLC Ordinary Shares
NASDAQ:CSHR
|
0.000x |
|
Gallant Precision Machining Co Ltd
TWO:5443
|
0.001x |
|
AUPU Home Style Corp Ltd
SHG:603551
|
0.023x |
|
Bannerman Energy Ltd
AU:BMN
|
-0.016x |
Annual Cash Flow Conversion Efficiency for AngioDynamics Inc (2002–2026)
The table below shows the annual cash flow conversion efficiency of AngioDynamics Inc from 2002 to 2026. Review how much free cash does AngioDynamics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-05-31 | $170.82 Million | $3.09 Million | 0.018x | +132.67% |
| 2025-05-31 | $182.97 Million | $-10.13 Million | -0.055x | +59.59% |
| 2024-05-31 | $205.59 Million | $-28.16 Million | -0.137x | -66527.12% |
| 2023-05-31 | $378.30 Million | $78.00K | 0.000x | +101.22% |
| 2022-05-31 | $424.49 Million | $-7.19 Million | -0.017x | -130.91% |
| 2021-05-31 | $439.46 Million | $24.09 Million | 0.055x | +271.73% |
| 2020-05-31 | $455.87 Million | $-14.55 Million | -0.032x | -152.43% |
| 2019-05-31 | $614.82 Million | $37.44 Million | 0.061x | -19.97% |
| 2018-05-31 | $542.60 Million | $41.29 Million | 0.076x | -29.43% |
| 2017-05-31 | $517.03 Million | $55.74 Million | 0.108x | +20.90% |
| 2016-05-31 | $507.03 Million | $45.22 Million | 0.089x | +89.23% |
| 2015-05-31 | $545.02 Million | $25.68 Million | 0.047x | +2.71% |
| 2014-05-31 | $537.89 Million | $24.68 Million | 0.046x | -9.30% |
| 2013-05-31 | $526.83 Million | $26.65 Million | 0.051x | +128.22% |
| 2012-05-31 | $523.39 Million | $11.60 Million | 0.022x | -73.44% |
| 2011-05-31 | $405.75 Million | $33.87 Million | 0.083x | -18.25% |
| 2010-05-31 | $391.35 Million | $39.96 Million | 0.102x | +90.57% |
| 2009-05-31 | $372.19 Million | $19.94 Million | 0.054x | -26.43% |
| 2008-05-31 | $355.71 Million | $25.91 Million | 0.073x | +178.55% |
| 2007-05-31 | $335.96 Million | $8.78 Million | 0.026x | +0.26% |
| 2006-05-31 | $123.44 Million | $3.22 Million | 0.026x | -73.25% |
| 2005-05-31 | $49.11 Million | $4.79 Million | 0.097x | +45.20% |
| 2004-05-31 | $37.23 Million | $2.50 Million | 0.067x | -85.31% |
| 2003-05-31 | $1.49 Million | $680.00K | 0.457x | +111.18% |
| 2002-05-31 | $-295.00K | $1.21 Million | -4.088x | -- |
About AngioDynamics Inc
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vesse… Read more